903 related articles for article (PubMed ID: 15735016)
21. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
22. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
23. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
24. [Detection of translocation t(8;14)(q24;132) in pediatric Burkitt's lymphomas using "long distance" polymerase chain reaction: a new method for diagnosis of Burkitt's lymphomas].
zur Stadt U; Reiter A; Welte K; Sykora KW
Klin Padiatr; 1997; 209(4):165-71. PubMed ID: 9340426
[TBL] [Abstract][Full Text] [Related]
25. [Epstein-Barr virus and Burkitt's lymphoma].
Joab I
Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
[TBL] [Abstract][Full Text] [Related]
26. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
27. Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia.
Kobayashi S; Taki T; Chinen Y; Tsutsumi Y; Ohshiro M; Kobayashi T; Matsumoto Y; Kuroda J; Horiike S; Nishida K; Taniwaki M
Genes Chromosomes Cancer; 2011 Apr; 50(4):207-16. PubMed ID: 21319257
[TBL] [Abstract][Full Text] [Related]
28. [Diffuse large B-cell lymphoma mainly involving the heart and showing t(8;14) (q24;q32) with c-myc rearrangement].
Takai K; Sanada M; Hirose Y; Shibuya H
Rinsho Ketsueki; 1997 Sep; 38(9):757-62. PubMed ID: 9364867
[TBL] [Abstract][Full Text] [Related]
29. Burkitt t(8;14)(q24;q32) and cryptic deletion in a CLL patient: report of a case and review of literature.
Reddy K; Satyadev R; Bouman D; Hibbard MK; Lu G; Paolo R
Cancer Genet Cytogenet; 2006 Apr; 166(1):12-21. PubMed ID: 16616107
[TBL] [Abstract][Full Text] [Related]
30. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
[TBL] [Abstract][Full Text] [Related]
31. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
32. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma.
Welzel N; Le T; Marculescu R; Mitterbauer G; Chott A; Pott C; Kneba M; Du MQ; Kusec R; Drach J; Raderer M; Mannhalter C; Lechner K; Nadel B; Jaeger U
Cancer Res; 2001 Feb; 61(4):1629-36. PubMed ID: 11245476
[TBL] [Abstract][Full Text] [Related]
33. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
[TBL] [Abstract][Full Text] [Related]
34. Infrequent p53 mutation in mouse tumors with deregulated myc.
Gutierrez MI; Bhatia K; Siwarski D; Wolff L; Magrath IT; Mushinski JF; Huppi K
Cancer Res; 1992 Feb; 52(4):1032-5. PubMed ID: 1737333
[TBL] [Abstract][Full Text] [Related]
35. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
Silva S; Kovalchuk AL; Kim JS; Klein G; Janz S
Cancer Res; 2003 Dec; 63(24):8656-63. PubMed ID: 14695177
[TBL] [Abstract][Full Text] [Related]
36. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
37. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line.
Kiem HP; Nourse J; Saltman DL; Blume KG; Cleary ML
Oncogene; 1990 Dec; 5(12):1815-9. PubMed ID: 2284100
[TBL] [Abstract][Full Text] [Related]
38. Illegitimate recombinations between c-myc and immunoglobulin loci are remodeled by deletions in mouse plasmacytomas but not in Burkitt's lymphomas.
Müller JR; Janz S; Potter M
Curr Top Microbiol Immunol; 1995; 194():425-9. PubMed ID: 7895518
[TBL] [Abstract][Full Text] [Related]
39. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
40. Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology.
Ruminy P; Jardin F; Picquenot JM; Gaulard P; Parmentier F; Buchonnet G; Maisonneuve C; Tilly H; Bastard C
Oncogene; 2006 Aug; 25(35):4947-54. PubMed ID: 16619046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
